Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.9K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.9K
Drug Discovery: Overview01:26

Drug Discovery: Overview

12.6K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
12.6K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

59
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
59
Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

55
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
55
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

10.9K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.9K
Measurement of Bioavailability: Pharmacodynamic Methods01:20

Measurement of Bioavailability: Pharmacodynamic Methods

936
Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
936

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ToxiSpecies: Task-Aware Meta-Learning for Cross-Species Modeling of Acute Chemical Toxicity under Distribution Shift.

Journal of chemical information and modeling·2026
Same author

Generative pretraining for drug molecule design with bidirectional structure-property optimization.

Communications chemistry·2026
Same author

Genome-guided generative adversarial learning enables nanopore adaptive sequencing.

Nature communications·2026
Same author

ToxiGuard: an AOP-guided mechanistically interpretable framework for multi-organ toxicity prediction.

Archives of toxicology·2026
Same author

Large-scale data-driven pre-trained DNA models enhance performance across diverse genomics tasks.

Nature communications·2026
Same author

Effect of preoperative fasting on acute postoperative pain following cesarean section: a retrospective cohort study.

Annals of medicine and surgery (2012)·2026

Related Experiment Video

Updated: Mar 12, 2026

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
10:21

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA

Published on: February 23, 2024

3.9K

A meta learning and task adaptive approach for drug target affinity prediction.

Mengxuan Wan1,2, Yanpeng Zhao1, Yixin Zhang2

  • 1School of Medicine, Shanghai University, Shanghai, China.

Nature Communications
|March 11, 2026
PubMed
Summary

AdaMBind, a novel meta-learning model, improves drug-target affinity (DTA) prediction in low-data situations. It enhances virtual screening and identifies potent inhibitors, offering a robust framework for few-shot DTA prediction.

More Related Videos

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro
05:50

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro

Published on: September 26, 2025

1.8K
Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis
08:49

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis

Published on: June 20, 2025

1.4K

Related Experiment Videos

Last Updated: Mar 12, 2026

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
10:21

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA

Published on: February 23, 2024

3.9K
Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro
05:50

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro

Published on: September 26, 2025

1.8K
Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis
08:49

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis

Published on: June 20, 2025

1.4K

Area of Science:

  • Computational chemistry
  • Pharmacology
  • Artificial intelligence in drug discovery

Background:

  • Accurate drug-target affinity (DTA) prediction is crucial for efficient drug discovery.
  • Current deep learning DTA models face challenges with limited data and poor generalization.
  • Addressing low-data scenarios is essential for advancing DTA prediction.

Purpose of the Study:

  • To introduce AdaMBind, a novel DTA prediction model utilizing a meta-learning framework.
  • To design an adaptive task module within AdaMBind for effective low-data DTA prediction.
  • To enhance training efficiency and robustness using a dynamic "easy-to-hard" task scheduling mechanism.

Main Methods:

  • Developed AdaMBind, a meta-learning based DTA prediction model.
  • Implemented an adaptive task module and dynamic "easy-to-hard" task scheduling.
  • Evaluated model performance on three benchmark datasets, focusing on few-shot learning conditions.

Main Results:

  • AdaMBind outperformed 8 baseline models in predicting affinity for unseen targets, especially in few-shot scenarios.
  • The model successfully identified high-affinity compounds for ESR and TP53 under stringent data constraints.
  • AdaMBind identified potent FLT3 inhibitors for acute myeloid leukemia, validated by preliminary experimental assays.

Conclusions:

  • AdaMBind offers a robust and effective framework for few-shot drug-target affinity prediction.
  • The meta-learning approach with adaptive tasks significantly improves DTA prediction accuracy in data-limited settings.
  • AdaMBind demonstrates practical utility in virtual screening and drug discovery for diseases like acute myeloid leukemia.